Table of Content

Introduction
Executive Summary
Acute Liver Failure: Overview
? Causes
? Mechanism of Action
? Signs and Symptoms
? Diagnosis
? Disease Management
Pipeline Therapeutics
? Comparative Analysis
Therapeutic Assessment
? Assessment by Product Type
? Assessment by Stage and Product Type
? Assessment by Route of Administration
? Assessment by Stage and Route of Administration
? Assessment by Molecule Type
? Assessment by Stage and Molecule Type
Acute Liver Failure – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
? Acute Liver Failure companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Acute Liver Failure Collaboration Deals
? Company-Company Collaborations (Licensing / Partnering) Analysis
? Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
? Comparative Analysis
ALXN1840: Alexion Pharmaceuticals
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report?..
Mid Stage Products (Phase II)
? Comparative Analysis
Bis-Choline Tetrathiomolybdate: Alexion Pharmaceuticals
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report?..
Early Stage Products (Phase I)
? Comparative Analysis
VTX-801: Vivet Therapeutics
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report?..
Preclinical Stage Products
? Comparative Analysis
Drug Name: Company name
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report?..
Inactive Products
? Comparative Analysis
Acute Liver Failure Key Companies
Acute Liver Failure Key Products
Acute Liver Failure- Unmet Needs
Acute Liver Failure- Market Drivers and Barriers
Acute Liver Failure- Future Perspectives and Conclusion
Acute Liver Failure Analyst Views
Acute Liver Failure Key Companies
Appendix



List of Figures


Figure 1 Total Products for Acute Liver Failure
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


List of Tables


Table 1 Total Products for Acute Liver Failure
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products